Billion-Dollar Bio Royalty Stocks Surge by 800 Billion Won in One Day Due to Strong Earnings

Royalty Pharma PLC (NASDAQ: RPRX) closed at $55.76 on May 28, up 2.35% on the Nasdaq. Trading volume reached 15.51 million shares—well above its average—and its market capitalization rose by about $590 million (roughly ₩810 billion), bringing the total to $24.7 billion (approximately ₩33.9 trillion), assuming an exchange rate of ₩1,370 per dollar.

In its first-quarter earnings announced on May 6, Royalty Pharma reported a robust growth trajectory, with portfolio receipts up 10% to $925 million and royalty revenues increasing 13%, prompting an upward revision of its full-year 2026 guidance. In April, the company also declared a second-quarter dividend and signed a joint R&D investment agreement with Johnson & Johnson, committing $500 million toward autoimmune drug development between 2026 and 2027, further boosting growth expectations.

Royalty Pharma is a specialist investment firm that acquires drug royalties and milestone rights from biopharmaceutical developers via upfront payments, then collects downstream sales royalties over the long term. Headquartered in New York, it operates an “asset-light” business model, securing steady cash flow through a diversified biopharmaceutical royalty portfolio.